{"doc_id": "33785743", "type of study": "Therapy", "title": "", "abstract": "Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.\nType III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19).\nWe conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint).\nIn both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19).\nSymptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39).\nBoth Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027).\nIn this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.\n", "Evidence Map": {"Enrollment": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 52}, {"term": "uncomplicated COVID-19", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 80}, {"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 102}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 133}, {"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 166}, {"term": "uncomplicated", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 185}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19 : a randomized placebo-controlled trial .", "Evidence Elements": {"Participant": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 52}, {"term": "uncomplicated COVID-19", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 80}], "Intervention": [{"term": "Peginterferon Lambda-1a", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We conducted a randomized , single-blind , placebo-controlled trial ( NCT04331899 ) in 120 outpatients with mild to moderate COVID-19 to determine whether a single , 180 mcg subcutaneous dose of Peginterferon Lambda-1a ( Lambda ) within 72 hours of diagnosis could shorten the duration of viral shedding ( primary endpoint ) or symptoms ( secondary endpoint ) .", "Evidence Elements": {"Participant": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 102}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 133}], "Intervention": [{"term": "Peginterferon Lambda-1a ( Lambda )", "negation": "affirmed", "UMLS": {}, "start": 195, "end": 229}], "Outcome": [{"term": "duration of viral", "negation": "affirmed", "UMLS": {}, "start": 277, "end": 294}], "Observation": [{"term": "shorten", "negation": "affirmed", "UMLS": {}, "start": 265, "end": 272}], "Count": []}, "Evidence Propositions": [{"Intervention": "Peginterferon Lambda-1a ( Lambda )", "Observation": "shorten", "Outcome": "duration of viral", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "In both the 60 patients receiving Lambda and 60 receiving placebo , the median time to cessation of viral shedding was 7 days ( hazard ratio [ HR ] = 0.81 ; 95 % confidence interval [ CI ] 0.56 to 1.19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Lambda", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 40}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 65}], "Outcome": [{"term": "median time to cessation of viral shedding", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 114}], "Observation": [{"term": "7 days", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 125}], "Count": []}, "Evidence Propositions": [{"Intervention": "Lambda", "Observation": "7 days", "Outcome": "median time to cessation of viral shedding", "Count": ""}, {"Intervention": "placebo", "Observation": "7 days", "Outcome": "median time to cessation of viral shedding", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Symptoms resolved in 8 and 9 days in Lambda and placebo , respectively , and symptom duration did not differ significantly between groups ( HR 0.94 ; 95 % CI 0.64 to 1.39 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Lambda", "negation": "negated", "UMLS": {}, "start": 37, "end": 43}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 48, "end": 55}, {"term": "between groups", "negation": "negated", "UMLS": {}, "start": 123, "end": 137}], "Outcome": [{"term": "Symptoms resolved", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 17}, {"term": "symptom duration", "negation": "negated", "UMLS": {}, "start": 77, "end": 93}], "Observation": [{"term": "8", "negation": "negated", "UMLS": {}, "start": 21, "end": 22}, {"term": "9 days", "negation": "negated", "UMLS": {}, "start": 27, "end": 33}, {"term": "differ significantly", "negation": "negated", "UMLS": {}, "start": 102, "end": 122}], "Count": []}, "Evidence Propositions": [{"Intervention": "Lambda", "Observation": "8", "Outcome": "Symptoms resolved", "Count": ""}, {"Intervention": "placebo", "Observation": "9 days", "Outcome": "Symptoms resolved", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Both Lambda and placebo were well-tolerated , though liver transaminase elevations were more common in the Lambda vs . placebo arm ( 15 / 60 vs 5 / 60 ; p=0.027 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Lambda", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 11}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 23}, {"term": "Lambda", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 11}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 23}], "Outcome": [{"term": "liver transaminase elevations", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 82}], "Observation": [{"term": "well-tolerated", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 43}, {"term": "more common", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 99}], "Count": [{"term": "60", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 140}, {"term": "60", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 140}]}, "Evidence Propositions": [{"Intervention": ["Lambda", "placebo"], "Observation": "more common", "Outcome": "liver transaminase elevations", "Count": ""}, {"Intervention": "Lambda", "Observation": "", "Count": "60", "Outcome": "liver transaminase elevations"}, {"Intervention": "placebo", "Observation": "", "Count": "60", "Outcome": "liver transaminase elevations"}]}, {"Section": "UNKNOWN", "Text": "In this study , a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19 .", "Evidence Elements": {"Participant": [{"term": "outpatients", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 166}, {"term": "uncomplicated", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 185}], "Intervention": [{"term": "subcutaneous Peginterferon Lambda-1a", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 69}], "Outcome": [{"term": "duration of SARS-CoV-2 viral shedding", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 129}, {"term": "symptoms", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 151}], "Observation": [{"term": "shortened", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 87}, {"term": "improved", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 142}], "Count": []}, "Evidence Propositions": [{"Intervention": "subcutaneous Peginterferon Lambda-1a", "Observation": "shortened", "Outcome": "duration of SARS-CoV-2 viral shedding", "Count": ""}]}]}